Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Internal Medicine | Allergy | ENT | Pharmacy | Pulmonology | Journal

Back to Journal Articles

Gabapentin Efficacious for Refractory Chronic Cough

Last Updated: August 28, 2012.

 

Improved cough-specific quality of life for patients treated with 10 weeks of gabapentin

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with refractory chronic cough, treatment with gabapentin is associated with improved cough-specific quality of life and is well-tolerated, according to a study published online Aug. 28 in The Lancet.

TUESDAY, Aug. 28 (HealthDay News) -- For patients with refractory chronic cough, treatment with gabapentin is associated with improved cough-specific quality of life and is well-tolerated, according to a study published online Aug. 28 in The Lancet.

Nicole M. Ryan, Ph.D., from The University of Newcastle in Australia, and colleagues examined the efficacy of gabapentin for 62 patients with refractory chronic cough seen at an outpatient clinic in Australia. Participants with refractory chronic cough of more than eight weeks' duration, without active respiratory disease or infection, were randomized to gabapentin (32 patients) or matching placebo (30 patients) for 10 weeks.

The researchers found that, compared with placebo, gabapentin significantly improved cough-specific quality of life (between-group difference in Leicester cough questionnaire score during treatment period, 1.80; P = 0.004). Thirty-one percent of gabapentin-treated patients experienced side effects, most commonly nausea and fatigue, as did 10 percent of placebo-treated patients.

"The treatment of refractory chronic cough with gabapentin is both effective and well tolerated," the authors write. "These positive effects suggest that central reflex sensitization is a relevant mechanism in refractory chronic cough."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Novel Agent Tolerable, Active for Advanced Colorectal Cancer Next: New Diagnostic Definition of Myocardial Infarction Issued

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.